^
CANCER:

Gastric Adenocarcinoma





Show legend
Group by Gene:
Include preclinical:

0
PD1 inhibitor
pembrolizumab
nivolumab
envafolimab
1
PD-L1 inhibitor
atezolizumab
PD-L1 inhibitor
2
HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
fam-trastuzumab deruxtecan-nxki
3
CLDN18.2 inhibitor
zolbetuximab
4
Thymidylate synthase inhibitor
5-fluorouracil
5
HER2 inhibitor
trastuzumab
HER2 inhibitor
6
Multi-tyrosine kinase inhibitor
pazopanib
nintedanib
7
PD-L1 inhibitor, HER2 inhibitor
trastuzumab + avelumab
8
ALK inhibitor
crizotinib
9
c-MET inhibitor
RG3638
AMG 102
10
VEGFR inhibitor, FGFR1 inhibitor, PD1 inhibitor
toripalimab-tpzi + surufatinib
11
Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
cisplatin + docetaxel + 5-fluorouracil
12
HER2 inhibitor, PD1 inhibitor
pembrolizumab + trastuzumab
pembrolizumab + margetuximab
13
Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor, Thymidylate synthase inhibitor
cisplatin + paclitaxel + capecitabine
14
FGFR inhibitor
futibatinib
15
Immunotherapy
Immunotherapy
No biomarker
HER-2 overexpression
HER-2 underexpression
HER-2 amplification
HER-2 negative
HER-2 positive
HER-2 1899‐1G>A
PD-L1 expression
PD-L1 underexpression
MET amplification
CLDN18.2 positive
CLDN18.2 expression
MET expression
ATR mutation
ATRX mutation
ATM mutation
MSI-H/dMMR
HER-2 negative + PD-L1 expression
CPEB1 underexpression
FGFR3 amplification
CDKN2A deletion
MDM4 amplification
MDM2 amplification
Chr amplification(11)(q13)
CMTM6 expression + PD-L1 expression
CDKN2B deletion
FGFR2 amplification
CMTM4 expression + PD-L1 expression